Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Learn more about Beckman Coulter's cardiovascular disease solutions at About Beckman Coulterīeckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Anagh Vora, chief medical officer, Beckman Coulter. This is an important biomarker in the diagnosis of heart failure (HF) and left ventricular dysfunction," said Dr. "BNP is a protein secreted by the ventricular musculature in response to volume or pressure overload on the heart. The speed and accuracy of the information a clinical laboratory delivers are critical to improving patient outcomes and reducing the cost of care. Clinical laboratories can support care for patients experiencing, or at risk for, cardiovascular disease. The cost of CVDs globally is estimated to rise to $1 trillion USD by 2030.
Four out of five CVD deaths are due to heart attacks and strokes, while one third of these deaths occur prematurely in people under 70 years of age.
Our panel of CVD assays supports advancing care for cardiac patients."Ĭardiovascular diseases account for an estimated 31% of all deaths worldwide and are the number one cause of death, globally killing ~17.9 million people each year. "Successful management of CVD means reducing the risk of adverse events by making the right decisions quickly. "We are excited to add Access BNP to Beckman Coulter's line of high-quality cardiac assays and provide a streamlined customer experience for our many customers that use this critical assay," said Julie Sawyer Montgomery, president, Beckman Coulter.
0 kommentar(er)
